It will be interesting to see what they come up with in the next trial results. I think at that point they will know what they have.I think this is a fair assessment assuming the product is approved.
Best case scenario to get FX-322 to approval is that it performs well on the common hearing assessments currently used in the clinic for a specific group that stands to show consistent improvement, reliably.
Based on what we know from the Phase 1/2, that's a patient group with moderate - moderately severe hearing loss. As for severe, there may be more missing support cells, but perhaps the hair cell situation is even worse, so triggering regeneration in even some of the remaining support cells may provide a measurable benefit.
I still think there is much more potential to FX-322 and they really need to figure out why they are not getting the results that they were expecting.